eCARTv5 Clinical Deterioration Suite (eCART) vs Tempus AI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

eCARTv5 Clinical Deterioration Suite (eCART)

by AgileMD

Tempus AI

by Tempus AI

AI Verdict

While both tools offer AI-powered clinical decision support and integrate with EHRs, they focus on different aspects of patient care. AgileMD's eCART is a broad clinical deterioration suite for hospitalized patients, predicting general risk of death or ICU transfer. Tempus AI, on the other hand, specializes in cardiovascular diagnosis and management through AI analysis of ECG data, identifying specific cardiac conditions like atrial fibrillation, low ejection fraction, pulmonary hypertension, and mitral regurgitation.

Choose eCARTv5 Clinical Deterioration Suite (eCART) if…

Choose eCARTv5 Clinical Deterioration Suite if your hospital needs a comprehensive, real-time AI solution for continuous monitoring and early prediction of general clinical deterioration (death or ICU transfer) across all hospitalized adult patients. This tool is ideal for institutions seeking to integrate AI-powered risk assessment and embedded clinical pathways directly into their EHR to proactively guide care and reduce critical events. It's particularly well-suited for critical care, emergency medicine, and hospital medicine departments aiming to minimize false alarms and clinician workload while improving patient outcomes.

View eCARTv5 Clinical Deterioration Suite (eCART) →

Choose Tempus AI if…

Choose Tempus ECG-AI Platform if your cardiology department or emergency medicine practice requires specialized AI-powered analysis of electrocardiogram data for advanced cardiovascular diagnosis and risk stratification. This tool is best for clinicians focused on identifying subtle ECG biomarkers, predicting cardiac events, and integrating precision medicine initiatives into their cardiovascular workflows. It is particularly valuable for enhancing the accuracy and depth of ECG interpretation to improve patient management in cardiology and emergency settings.

View Tempus AI →

When considering AI tools for clinical practice, physicians can choose between broad deterioration prediction and specialized diagnostic analysis. AgileMD’s eCARTv5 Clinical Deterioration Suite excels at continuous, real-time assessment of hospitalized adult patients, predicting the risk of death or ICU transfer hours in advance. It integrates directly with EHRs, leveraging up to 97 variables to provide an eCART score and risk designation, coupled with embedded clinical pathways for care guidance. This tool is best suited for hospitalists, critical care, and emergency medicine physicians who require an early warning system to proactively manage patient deterioration across a wide range of conditions.

In contrast, Tempus AI’s ECG-AI Platform focuses specifically on cardiovascular diagnosis and management by applying AI to electrocardiogram data. It offers advanced insights for risk stratification of cardiac events and identifies subtle ECG biomarkers, supporting precision medicine initiatives in cardiology. The key practical difference lies in their scope: eCART provides a generalized deterioration prediction across various patient populations and conditions, while Tempus AI offers deep, specialized analysis within the cardiovascular domain. Physicians in cardiology, or those in emergency medicine and internal medicine with a strong focus on cardiac care, would find Tempus AI more beneficial for enhancing their diagnostic capabilities and guiding treatment decisions for heart-related conditions.

Quick Comparison

Feature	eCARTv5 Clinical Deterioration Suite (eCART)	Tempus AI
Pricing	Contact vendor for tailored quote.	Unknown
Deployment	Cloud-based SaaS, integrated directly into Electronic Health Record (EHR) systems.	Cloud
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Unknown
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

eCARTv5 Clinical Deterioration Suite (eCART)

AgileMD's eCARTv5 is praised for its intuitive interface and seamless integration with existing EHRs, which helps streamline workflows and minimize false alarms. Tempus AI, while integrating with EHRs, focuses on filtering eligible patients and providing insights, with less explicit mention of an intuitive user interface for broad clinical use beyond specialized cardiology workflows.

Clinical Value

eCARTv5 Clinical Deterioration Suite (eCART)

AgileMD's eCARTv5 has demonstrated high accuracy in predicting clinical deterioration (death or ICU transfer) across various conditions, including sepsis and heart failure, and has undergone prospective validation. Tempus AI's ECG-AI platform offers advanced insights for cardiovascular diagnosis and risk stratification for cardiac events, with multiple FDA clearances for specific conditions like AFib, low LVEF, PH, and mitral regurgitation. However, eCARTv5's broader application as an 'all-cause clinical deterioration prediction device' for hospitalized adult patients suggests a wider immediate clinical impact across general hospital wards.

Pricing & Value

Tie

Both tools require contacting the vendor for a tailored quote, indicating a lack of public pricing transparency. Neither tool provides enough public information to definitively assess which offers superior value for money without a direct quote. Therefore, it is difficult to determine a winner in this dimension.

Enterprise Readiness

eCARTv5 Clinical Deterioration Suite (eCART)

AgileMD's eCARTv5 is FDA-cleared, HIPAA compliant, and integrates directly into EHR systems, with a cloud-based SaaS deployment. It has been implemented in over 200 U.S. hospitals and used by over 135,000 providers, demonstrating significant enterprise adoption and scalability. Tempus AI also boasts FDA clearances, HIPAA and GDPR compliance, and cloud deployment with API availability. However, AgileMD's extensive existing deployments and focus on EHR-integrated clinical pathways suggest a more mature enterprise readiness for widespread hospital implementation.

Innovation

Tempus AI

Tempus AI demonstrates strong innovation through its diverse portfolio of FDA-cleared AI-powered ECG analysis tools for various cardiovascular conditions (AFib, low LVEF, PH, mitral regurgitation), and its broader platform approach including genomic sequencing and a generative AI clinical assistant. AgileMD's eCARTv5 is also innovative with its AI-powered continuous risk assessment and embedded clinical pathways, and its prospective validation. However, Tempus's breadth of AI applications across different diagnostic areas within cardiology and its integration with genomic data for precision medicine gives it an edge in overall innovation.

Support & Docs

Tie

Both companies provide limited public information regarding their specific support and documentation offerings. While AgileMD mentions training resources and various support channels, and Tempus highlights its commitment to advancing cardiology through AI algorithms and integrating AI into workflows, neither provides enough detail to definitively declare a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	eCARTv5 Clinical Deterioration Suite (eCART)	Tempus AI
Name	eCARTv5 Clinical Deterioration Suite (u201ceCARTu201d)	Tempus AI
Company	AgileMD	Tempus AI
Description	FDA-cleared, AI-powered Software as a Medical Device (SaMD) that integrates with EHRs to continuously assess and predict the risk of clinical deterioration (death or ICU transfer) in hospitalized adult patients, guiding care with embedded clinical pathways.	Tempus ECG-AI Platform uses artificial intelligence to analyze electrocardiogram data, offering advanced insights for cardiovascular diagnosis and management.
Key Features	AI-powered clinical deterioration prediction, Continuous patient risk assessment (death or ICU transfer), EHR integration with real-time data (up to 97 variables), Embedded clinical pathways for care guidance, Early warning system (alerts hours before critical illness), Risk stratification (eCART score and risk designation), Minimizes false alarms and clinician workload, Reporting and benchmarking capabilities	AI-powered ECG analysis, Risk stratification for cardiac events, Integration with clinical workflows, Identification of subtle ECG biomarkers, Support for precision medicine initiatives
Specialties	Critical Care, Emergency Medicine, Hospital Medicine	Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring eCARTv5 Clinical Deterioration Suite (eCART) and Tempus AI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing EHR workflows and what is the typical learning curve for physicians?

eCARTv5 integrates directly into EHR systems, continuously monitoring up to 97 variables in real-time to assess and predict clinical deterioration, and provides embedded clinical pathways for care guidance. Tempus AI's ECG-AI Platform also employs EHR integrations to filter eligible patients and integrate AI-powered ECG analysis into clinical workflows for cardiovascular diagnosis and management. The learning curve for both tools would depend on the depth of their integration and the intuitiveness of their user interfaces within the EHR.

What is the accuracy and sensitivity of each tool in identifying relevant clinical conditions?

eCARTv5 has demonstrated high accuracy in predicting clinical deterioration (death or ICU transfer), with an AUROC of 0.834 in retrospective validation, outperforming other early warning scores. It maintains high performance across various patient demographics and clinical conditions, including sepsis, COPD, and heart failure. Tempus AI's ECG-AI Platform includes algorithms like Tempus ECG-AF, which can detect signs associated with atrial fibrillation within 12 months, with AF observed in approximately 1-in-5 patients receiving a positive result. Tempus ECG-Low EF detects signs associated with a low left ventricular ejection fraction (LVEF less than or equal to 40%) in patients 40 years or older at risk of heart failure, and Tempus ECG-MR detects signs associated with undiagnosed moderate or severe mitral regurgitation.

For which medical specialties are these tools most appropriate, and what specific clinical contexts do they address?

eCARTv5 is primarily designed for Critical Care, Emergency Medicine, and Hospital Medicine, focusing on the early detection and management of all-cause clinical deterioration in hospitalized adult patients. Tempus AI's ECG-AI Platform is tailored for Cardiology, Emergency Medicine, and Internal Medicine, providing advanced insights for cardiovascular diagnosis and management, including risk stratification for cardiac events and identification of subtle ECG biomarkers.

What kind of support and resources are available for physicians during implementation and ongoing use?

While specific details on support quality are not provided, both companies offer AI-powered solutions for healthcare. AgileMD emphasizes its 'great team' and the platform's ability to 'help reduce mortality and improve care to our patients in real time 24/7'. Tempus AI aims to provide physicians with tools that learn as more data is gathered, suggesting ongoing development and support for their precision medicine initiatives.

What audit-trail features are available to track the tool's recommendations and their impact on patient care?

eCARTv5 provides reporting and benchmarking capabilities, which would likely include features for tracking the impact of its predictions and embedded clinical pathways. Tempus AI's integration with clinical workflows and support for precision medicine initiatives suggest that there would be mechanisms to track the use and outcomes of its ECG analysis, though specific audit-trail features are not detailed.